MedTrace Logo

PRP for Treatment of Peyronie's Disease

NCT04512287 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 65

Last updated 2025-08-14

No results posted yet for this study

Summary

The purpose of this study is to learn about the effects of Platelet-Rich Plasma (PRP) injection in men with Peyronie's Disease (PyD).

Conditions

  • Peyronie Disease
  • Sexual Dysfunction, Physiological
  • Sexual Dysfunction Male
  • Genital Diseases, Male

Interventions

DRUG

Autologous Platelet Rich Plasma

2 sessions of Autologous PRP will be administered 15 days apart. Each injection will be 0.5 mL of PRP injected into the Peyronie's disease penile plaque.

OTHER

Saline Solution

2 sessions of saline injection will be administered 15 days apart. Each injection will be 0.5 mL of normal saline injected into the Peyronie's disease penile plaque.

Sponsors & Collaborators

  • University of Miami

    lead OTHER

Principal Investigators

  • Manuel Molina, MD · University of Miami

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-29
Primary Completion
2025-08-11
Completion
2025-08-11
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04512287 on ClinicalTrials.gov